Gilead Sciences (GILD) Stock Forecast & Price Target

$85.21

+0.78 (+0.92%)

(As of 10/8/2024 ET)

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
11

Buy
9

Based on 20 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 11 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for GILD.

Consensus Price Target

$83.94
-1.49% Downside

According to the 20 analysts' twelve-month price targets for Gilead Sciences, the average price target is $83.94. The highest price target for GILD is $105.00, while the lowest price target for GILD is $69.00. The average price target represents a forecasted downside of -1.49% from the current price of $85.21.

Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

GILD Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	10 Buy rating(s)
Hold	11 Hold rating(s)	12 Hold rating(s)	12 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$83.94	$82.06	$84.00	$90.05
Forecasted Upside	-1.49% Downside	4.24% Upside	22.18% Upside	19.97% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Moderate Buy

[SHOCKING] Crypto Document Leak… (Ad)

The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.

Download your digital copy now

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences Stock vs. The Competition

Type	Gilead Sciences	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	-1.06% Downside	10,819.51% Upside	7.88% Upside
News Sentiment Rating	Positive News See Recent GILD News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/7/2024	Barclays 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$76.00 ➝ $84.00	-1.32%
10/7/2024	Wells Fargo & Company 3 of 5 stars	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$78.00 ➝ $100.00	+17.21%
10/4/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Sector Perform ➝ Sector Perform	$74.00 ➝ $75.00	-11.04%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$70.00 ➝ $70.00	-15.63%
9/11/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$95.00 ➝ $95.00	+18.62%
8/15/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$82.00 ➝ $83.00	+11.98%
Get the Latest News and Ratings for GILD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.
8/15/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
8/9/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/9/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$80.00 ➝ $85.00	+12.45%
7/8/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$93.00	+39.45%
6/20/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$80.00 ➝ $80.00	+15.82%
5/1/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$90.00 ➝ $85.00	+30.37%
4/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$80.00 ➝ $78.00	+19.28%
4/26/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$90.00 ➝ $85.00	+29.99%
4/24/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$69.00	+2.99%
4/19/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$105.00	+58.01%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$81.00 ➝ $75.00	+12.06%
2/22/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$101.00 ➝ $90.00	+24.76%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$75.00	-3.72%
10/11/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Graybosch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
9/8/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$88.00 ➝ $95.00	+28.48%
2/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$90.00 ➝ $95.00	+11.07%
2/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform	$81.00 ➝ $91.00	+8.23%
12/9/2022	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$90.00	+0.59%
11/9/2022	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$70.00 ➝ $100.00	+21.61%
11/8/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$80.00 ➝ $90.00	+9.45%
10/28/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$80.00 ➝ $87.00	+11.72%
10/28/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$78.00 ➝ $86.00	+10.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:37 PM ET.

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 1, 2024. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

Gilead Sciences, Inc. has a strong track record of developing innovative medicines to address unmet medical needs, which can lead to significant revenue growth.
The company recently announced a quarterly dividend of $0.77 per share, indicating a stable dividend payout that can attract income-focused investors.
Analysts have set an average target price of $82.06 for Gilead Sciences, Inc., suggesting potential for stock price appreciation from the current levels.
Recent upgrades by research firms to "strong-buy" and "overweight" ratings indicate positive sentiment and confidence in the company's future performance.
Gilead Sciences, Inc. has a diverse portfolio of products and ongoing research efforts, reducing dependency on any single product for revenue generation.

Gilead Sciences
Bear Case

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

The stock of Gilead Sciences, Inc. has a high price-to-earnings ratio of 232.89, which may indicate an overvalued position in the market.
The company's dividend payout ratio of 855.56% raises concerns about sustainability and potential limitations on future dividend growth.
Gilead Sciences, Inc. faces competition in the biopharmaceutical industry, which could impact market share and profitability in the long term.
The company's beta of 0.18 suggests low volatility compared to the market, potentially limiting opportunities for short-term gains for traders seeking high volatility stocks.
While Gilead Sciences, Inc. has shown positive earnings results, the PE ratio of 232.89 and price-to-earnings-growth ratio of 2.91 may indicate a premium valuation that could deter value investors.

GILD Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $83.94, with a high forecast of $105.00 and a low forecast of $69.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 11 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GILD shares.
: According to analysts, Gilead Sciences's stock has a predicted downside of -1.49% based on their 12-month stock forecasts.
: Over the previous 90 days, Gilead Sciences's stock had 2 upgrades by analysts.
: Gilead Sciences has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Evercore ISI, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Gilead Sciences less than other "medical" companies. The consensus rating score for Gilead Sciences is 2.50 while the average consensus rating score for "medical" companies is 2.78. Learn more on how GILD compares to other companies.